

|  |  |  |
| --- | --- | --- |
|  |  | **Volume 17 Number 11**  **November 2011**    **An unusual adverse effect of nadroparin injections: Calcinosis cutis  Almudena Nuno-Gonzalez1, Leticia Calzado-Villarreal1, Marta Gutierrez-Pascual1, Reyes Gamo-Villegas1, Henar Sanz-Robles1, Araceli Sanchez-Gilo1, Fernando Pinedo-Moraleda2, Jose Luis Lopez-Estebaranz1 Dermatology Online Journal 17 (11): 4**  1. Unit of Dermatology 2. Unit of Pathology Hospital Universitario Fundacion Alcorcon, Madrid, Spain |

|  |  |  |
| --- | --- | --- |
|  |  | **Abstract**  In 1988, Tumiati et al described the first case of calcinosis cutis related to a calcium-containing heparin. Since then, only 18 cases have been reported in the literature; they usually have an altered calcium-phosphate product, an elevated parathyroid hormone (PTH), or both. We report a 33-year-old patient who developed calcinosis cutis at sites of nadroparin injections without any disturbance of calcium-phosphate product, PTH, or vitamin D. The pathogenesis of calcinosis cutis secondary to nadroparin injections remains controversial; Proposed causes included metastatic, dystrophic, iatrogenic, or multifactorial etiologies. This is the first case of multiple nodules of calcinosis cutis without alterations of calcium-phosphate product, PTH, or vitamin D, which supports an iatrogenic mechanism. We also suggest that calcinosis cutis could be more frequent than we thought and is probably an underdiagnosed entity |